Abstract

High-risk HPV is found in 99.7% of cervical cancers. The causative role of HPV in cervical cancer has led to the inclusion of HPV testing as part of cervical screening. A pilot of HPV testing as primary screening was commenced in 2013 at six pilot sites in England. North Cumbria Integrated Care (NCIC) NHS Foundation Trust took part in the pilot, in which women with an HPV-positive/cytology-negative result were recalled at 12 months. Women with HPV type 16/18 found at initial screening and persisting at 12 months in spite of negative cytology were referred to Colposcopy services at 12 months. Women with smear positive for hrHPV other than 16/18 types were recalled twice at 12 and 24 months before referral to colposcopy. Persistent hrHPV positive/cytology negative smear at 12 and 24 months initiated a colposcopy referral. Objective: To assess the prevalence of high grade CIN and invasive cancer in patients referred to colposcopy services at NCIC NHS Foundation Trust with hrHPV positive/cytology negative smears. Method: The study was conducted at NCIC NHS Foundation Trust between January 2015 and December 2017. Data was collected retrospectively from the colposcopy data base (INFOFLEX). All patients with HPV positive/cytology negative smears seen in colposcopy clinic during the study period were included. Patients with high grade CIN, cervical glandular intraepithelial neoplasia (CGIN) or invasive cancer were recorded. Results: 763 women were included in the study. A total of 50 (6.6%) women had high grade CIN, CGIN or invasive cancer. 40 of these 50 women (80%) were treated by large loop excision of the transformation zone (LLETZ). Conclusion: HPV primary screening is more effective than cytology-based screening. A high grade HPV positive result with negative cytology, persisting for one year in type 16/18 and for two years in other high-risk HPV types, warrants referral for colposcopy, as 6.6% of women in this study had high grade or invasive pathology.

Highlights

  • Cervical cancer is ranked as the fourth most common cause of cancer incidence and mortality in women worldwide [1]

  • Evidence suggests that using high risk human papillomavirus (hrHPV) DNA testing as the primary test in cervical screening is more sensitive for detecting cervical intraepithelial neoplasia (CIN) and provides greater protection against cervical cancer [3] [4] [5] [6] [7]

  • A total of 6895 women were seen in colposcopy services at North Cumbria Integrated Care (NCIC) NHS Foundation Trust across two sites

Read more

Summary

Introduction

Cervical cancer is ranked as the fourth most common cause of cancer incidence and mortality in women worldwide [1]. A well organized and quality assured cervical screening programme can reduce cervical cancer incidence by over 80% [2]. In UK, the NHS National Cervical Screening Programme (NHSSCP) was launched in 1988. The cervical screening programme was cytology based, the causative role of high risk human papillomavirus (hrHPV) has led to inclusion of hrHPV testing as a part of cervical screening. HPV triage of mild and borderline cytology and test of cure for treated cases was introduced into the NHS National Cervical Screening Programme in the UK in 2012 [8]. Introduction of HPV triage to liquid based cytology screening was concluded to be feasible, acceptable to women and cost effective in terms of quality and of life years saved [9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call